4-Cholesten 3-One

4-Cholesten 3-One

SCHEMBL601331

CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C.CO

nearest known ligand 0.79

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1L1 Q9UHC9 1/20 0.79
PTPN1 P18031 1/20 0.73
CYP17A1 P05093 4/20 0.71
MAPT P10636 2/20 0.71
KDM4E B2RXH2 1/20 0.71
SMN1; SMN2 Q16637 1/20 0.71
USP2 O75604 2/20 0.65
LMNA P02545 5/20 0.64
HSD17B10 Q99714 3/20 0.64
CYP3A4 P08684 3/20 0.64
TSHR P16473 3/20 0.64
NR3C1 P04150 2/20 0.64
SHBG P04278 2/20 0.64
PGR P06401 2/20 0.64
SERPINA6 P08185 2/20 0.64
AR P10275 2/20 0.64
CYP19A1 P11511 2/20 0.64
SNCA P37840 2/20 0.64
CACNA1C Q13936 2/20 0.64
CYP51A1 Q16850 2/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
4-Cholesten 3-One SCHEMBL55896 0.98 NPC1L1 (0.79) NPC1L1PTPN1CYP17A1MAPTKDM4E
4-Cholesten 3-One SCHEMBL19506686 0.98 NPC1L1 (0.79) NPC1L1PTPN1CYP17A1MAPTKDM4E
4-Cholesten 3-One SCHEMBL2600424 0.98 NPC1L1 (0.79) NPC1L1PTPN1CYP17A1MAPTKDM4E
4-Cholesten 3-One SCHEMBL23452819 0.98 NPC1L1 (0.79) NPC1L1PTPN1CYP17A1MAPTKDM4E
4-Cholesten 3-One SCHEMBL10308280 0.98 NPC1L1 (0.79) NPC1L1PTPN1CYP17A1MAPTKDM4E
4-Cholesten 3-One SCHEMBL24151936 0.98 NPC1L1 (0.79) NPC1L1PTPN1CYP17A1MAPTKDM4E
4-Cholesten 3-One SCHEMBL20094570 0.98 NPC1L1 (0.79) NPC1L1PTPN1CYP17A1MAPTKDM4E
4-Cholesten 3-One SCHEMBL25996870 0.98 NPC1L1 (0.79) NPC1L1PTPN1CYP17A1MAPTKDM4E
4-Cholesten 3-One SCHEMBL21176042 0.98 NPC1L1 (0.79) NPC1L1PTPN1CYP17A1MAPTKDM4E
4-Cholesten 3-One SCHEMBL1688732 0.98 NPC1L1 (0.79) NPC1L1PTPN1CYP17A1MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2130916-B1 E. COLI CAPABLE OF EXPRESSING CYTOCHROME P-450, AND BIOCONVERSION METHOD USING THE SAME MICROBIOPHARM JAPAN CO LTD (JP) 2015-09-02 EP disclosed
US-8735135-B2 Transformed strains originated from multidrug efflux protein defective strains and a method for microbial conversion using them MICROBIOPHARM JAPAN CO., LTD (JP) 2014-05-27 US disclosed
EP-2130907-B1 TRANSFORMED STRAIN DERIVED FROM STRAIN DEFICIENT IN MULTIDRUG EFFLUX PROTEIN, AND BIOCONVERSION METHOD USING THE SAME MICROBIOPHARM JAPAN CO LTD (JP) 2013-06-12 EP disclosed
US-8460915-B2 Escherichia coli expressing the cytochrome P-450 gene and a method for microbial conversion using them MICROBIOPHARM JAPAN CO., LTD. (JP) 2013-06-11 US disclosed
US-20120040441-A1 TRANSFORMED STRAINS ORIGINATED FROM MULTIDRUG EFFLUX PROTEIN DEFECTIVE STRAINS AND A METHOD FOR MICROBIAL CONVERSION USING THEM MERCIAN CORPORATION (JP) 2012-02-16 US disclosed
US-20100285565-A1 ESCHERICHIA COLI EXPRESSING THE CYTOCHROME P-450 GENE AND A METHOD FOR MICROBIAL CONVERSION USING THEM SANLI HOLDINGS CO., LTD. (JP) 2010-11-11 US disclosed
EP-2130916-A1 E. COLI CAPABLE OF EXPRESSING CYTOCHROME P-450, AND BIOCONVERSION METHOD USING THE SAME MERCIAN CORPORATION (JP) 2009-12-09 EP disclosed
EP-2130907-A1 TRANSFORMED STRAIN DERIVED FROM STRAIN DEFICIENT IN MULTIDRUG EFFLUX PROTEIN, AND BIOCONVERSION METHOD USING THE SAME MERCIAN CORPORATION (JP) 2009-12-09 EP disclosed